RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Currency in ILS

Valuation Measures

Market Cap (intraday) 5718.01M
Enterprise Value 3696.86M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)104.59
Price/Book (mrq)2,259.82
Enterprise Value/Revenue 3101.51
Enterprise Value/EBITDA 6-17.05

Trading Information

Stock Price History

Beta (3Y Monthly) 0.56
52-Week Change 3-4.71%
S&P500 52-Week Change 31.68%
52 Week High 3343.00
52 Week Low 3183.00
50-Day Moving Average 3249.46
200-Day Moving Average 3275.59

Share Statistics

Avg Vol (3 month) 3187.68k
Avg Vol (10 day) 3145.99k
Shares Outstanding 5283.69M
Float 131.6M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-602.65%

Management Effectiveness

Return on Assets (ttm)-59.07%
Return on Equity (ttm)-133.35%

Income Statement

Revenue (ttm)6.87M
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)-33.50%
Gross Profit (ttm)5.52M
EBITDA -40.87M
Net Income Avi to Common (ttm)-38.55M
Diluted EPS (ttm)-0.15
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)34.87M
Total Cash Per Share (mrq)0.12
Total Debt (mrq)4.07M
Total Debt/Equity (mrq)12.76
Current Ratio (mrq)2.84
Book Value Per Share (mrq)0.11

Cash Flow Statement

Operating Cash Flow (ttm)-34.55M
Levered Free Cash Flow (ttm)-20.35M